Powered by 
Technavio
VBL Therapeutics | Data-Driven Analysis and Industry Review
Published: August 21, 2024VBL Therapeutics is a clinical-stage biotech company focused on the development of novel therapies for the treatment of cancer and orphan diseases. The company's lead program, VB-111, is a first-in-class, targeted immunotherapy using a proprietary platform technology called Epigenetic Binucleotide Replacements (EBR). VB-111 is designed to selectively target and reactivate tumor suppressor genes in cancer cells, enhancing the body's immune response against the tumor. VBL Therapeutics is headquartered in Israel and has ongoing clinical trials in multiple indications, including hematological malignancies and solid tumors. The company's mission is to bring innovative and effective treatments to patients in need, leveraging its unique technology platform and scientific expertise.'
1. Focus on developing gene therapy products: VBL Therapeutics specializes in the research and development of gene therapy treatments for various diseases, including cancer and inherited genetic disorders.
2. Proprietary technology platform: The company's technology platform, called "VaxxiPlasmid," utilizes a unique approach to deliver therapeutic genes directly into cells, enabling potential for long-term expression and improved efficacy.
3. Clinical-stage pipeline: VBL Therapeutics has a clinical-stage pipeline with multiple product candidates in development, including VB-111 for the treatment of hepatocellular carcinoma and VB-201 for the treatment of metastatic colorectal cancer.
4. Strategic collaborations: The company has formed partnerships with leading institutions and organizations, such as the National Institutes of Health (NIH) and the European Organisation for Research and Treatment of Cancer (EORTC), to advance its research and development efforts.
5. Experienced management team: VBL Therapeutics boasts a team of experienced industry veterans with a track record of success in bringing innovative therapies to market, increasing the chances of bringing its pipeline products to fruition.
1. VBL Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of novel therapies for the treatment of severe and life-threatening diseases, with a focus on oncology and immunology.
2. They employ a unique, proprietary technology platform called "Vaximmune" which combines in vivo gene therapy with immune system activation, enabling the development of therapeutic vaccines and immunotherapies.
3. Their lead product, VB-111, is a gene therapy for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer, which is currently in Phase 3 clinical trials.
4. VBL Therapeutics also has a pipeline of preclinical programs, including VB-201 for the treatment of multiple myeloma and VB-300 for the treatment of solid tumors, which are being developed using their Vaximmune technology.
5. The company has collaborations with leading research institutions and pharmaceutical companies, including the National Cancer Institute, Memorial Sloan Kettering Cancer Center, and Merck KGaA, to advance their research and development efforts.
Browse Our Research Portfolio In VBL Therapeutics Markets
Health Care
Pharmaceuticals
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
